Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Acid phosphatase (acp1)gene as a susceptibility locus for hyperlipidemia

a susceptibility locus and acid phosphatase technology, applied in the field of human genetics, can solve the problems of increased risk of cad and non-insulin-dependent diabetes mellitis (niddm), and achieve the effect of reducing the probability of developing hyperlipidemia

Inactive Publication Date: 2005-03-10
BURNHAM INST FOR MEDICAL RES +1
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006] The present invention provides diagnostic and prognostic methods for detecting a predisposition to hyperlipidemia, especially hyperlipidemia associated with metabolic disease, by detecting a non-*A allele at the APC1 locus, or confirming the lack of a predisposition by detecting the presence of the *A allele at the APC1 locus. Methods of treating, or reducing the probability of developing hyperlipidemia and metabolic disease are also provided.

Problems solved by technology

However, it has remained unclear what distinguishes those individuals whose weight gain leads to the development of the metabolic syndrome from those more fortunate persons who appear capable of considerable weight gain without experiencing the dyslipidemia and insulin resistance that trigger increased risk of developing CAD and non-insulin-dependent diabetes mellitis (NIDDM).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acid phosphatase (acp1)gene as a susceptibility locus for hyperlipidemia

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0078] A study was performed at the Center for Health Promotion at Loma Linda University Medical Center, Loma Linda, Calif. Non-Hispanic Caucasian females (average age 54.5±6.5 [SD] years) with a lifetime history of obesity (average BMI 39.1±7.5 [SD]) were recruited from the community by newspaper ads. To obtain a broad range of BMI, each currently obese subject was asked to bring to the clinic an age matched non-obese friend from her own ethnic, educational and social class. Using the criteria described by Trakas et al (13) subjects were classified into three weight groups: BMI≦29=non-obese; BMI30-34=obese; BMI≧35=morbidly obese. The obese and morbidly obese subjects had an average BMI of 39.1±7.5 [SD]. The non-obese subjects had an average BMI of 24.0±2.7 [SD]. All subjects were unrelated, were drug-free, and were specifically not taking lipid lowering agents or blood pressure medication. Blood lipid levels were performed on individuals fasted overnight. The cholesterol, triglycer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Disorderaaaaaaaaaa
Enzyme activityaaaaaaaaaa
Login to View More

Abstract

The ACP1 *A allele provides a means for diagnosing susceptability of a human subject to hyperlipidemia, especially hyperlipidemia associated with metabolic syndrome, a means for treating, or preventing the onset of, hyperlipidemia and metabolic syndrome, and a means for screening and identifying drugs suitable for use in treating or preventing hyperlipidemia, especially hyperlipidemia associated with metabolic syndrome. Diagnostic kits are also provided.

Description

FIELD OF THE INVENTION [0001] This invention relates generally to the field of human genetics. More specifically, the invention relates to diagnosis of susceptibility to hyperlipidemia, especially hyperlipidemia associated with metabolic syndrome. The invention further relates to methods for screening drug candidates for suitability in the treatment of hyperlipidemia and metabolic syndrome, and to methods for treating or preventing hyperlipidemia, especially hyperlipidemia associated with metabolic syndrome. [0002] The publications and other materials used herein to illuminate the background of the invention or provide additional details respecting the practice are incorporated by reference. BACKGROUND OF THE INVENTION [0003] Increased incidence of obesity, hyperlipidemia, hypertension, non-insulin dependent diabetes and coronary artery disease often cluster in the same individuals, and it has been frequently asserted that a common mechanism may be responsible for the comorbidity of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A01K67/027C12Q1/68
CPCC12Q2600/156C12Q1/6883A61P3/06
Inventor COMINGS, DAVID EMACMURRAY, JAMES P.BOTTINI, NUNZIO
Owner BURNHAM INST FOR MEDICAL RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products